Combined BRAF-MEK inhibition better than single-agent therapy in MM

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Several recent randomized clinical trials have demonstrated that initial targeted therapy with combined BRAF and MEK inhibition is more effective in metastatic melanoma (MM) than single agent. A recent comprehensive meta-analysis confired that concurrent inhibition of BRAF and MEK was the most effective therapeutic modality compared with single BRAF or MEK inhibition for patients with MM.

Method

  • PubMed and trial registries searched for randomized clinical trials of targeted therapy
  • Outcomes data extracted on progression-free survival (PFS), objective response rate (ORR), and overall survival (OS)
  • Network meta-analysis (Bayesian statistical model) performed to evaluate relative hazard ratio (HR) for PFS and OS, odds ratio (OR) for ORR
  • 16 el...